Blueprint Medicines Corp Aktie
-
Deine Einschätzung
Blueprint Medicines Corp Aktie
Was spricht für und gegen Blueprint Medicines Corp in den nächsten Jahren?
Pro
Kontra
Rendite von Blueprint Medicines Corp im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | 1,55 % | 0,00 % | 18,07 % | 105,24 % | 18,07 % | 180,00 % | 61,38 % |
| United Therapeutics | 1,15 % | -0,65 % | -5,14 % | 82,53 % | 13,97 % | 133,01 % | 186,47 % |
| Ionis Pharmaceuticals Inc. | 0,22 % | 0,50 % | 0,73 % | 135,38 % | -6,21 % | 98,63 % | 78,89 % |
Kommentare
News
Spirits on the Rocks? The Battle for Jack Daniels
The global premium spirits sector is navigating a significant shift. After a period of high consumer demand driven by COVID-era stay-at-home trends, the market is now normalizing. This return to
Irresistible Change: How to Spot Real Growth
Phil Gilbert, serial entrepreneur and former general manager at IBM, joins this episode of Motley Fool Money to talk about his new book, Irresistible Change: A Blueprint for Earning Buy-In and
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock





